Main content area

Functional expression of sodium-glucose transporters in cancer

Scafoglio, Claudio, Hirayama, Bruce A., Kepe, Vladimir, Liu, Jie, Ghezzi, Chiara, Satyamurthy, Nagichettiar, Moatamed, Neda A., Huang, Jiaoti, Koepsell, Hermann, Barrio, Jorge R., Wright, Ernest M.
Proceedings of the National Academy of Sciences of the United States of America 2015 v.112 no.30 pp. E4111
animal models, glucose, glucose transporters, image analysis, neoplasm cells, patients, positron-emission tomography, prostatic neoplasms, viability
Cancers require high amounts of glucose to grow and survive, and dogma is that uptake is facilitated by passive glucose transporters (GLUTs). We have identified a new mechanism to import glucose into pancreatic and prostate cancer cells, namely active glucose transport mediated by sodium-dependent glucose transporters (SGLTs). This means that the specific radioactive imaging probe for SGLTs, α-methyl-4-deoxy-4-[ ¹⁸F]fluoro- d -glucopyranoside, may be used along with positron-emission tomography to diagnose and stage pancreatic and prostate cancers, tumors in which the GLUT probe 2-[ ¹⁸F]fluoro-2-deoxy- d -glucose has questionable utility. Moreover, we suggest, based on our results in mouse models, that Food and Drug Administration-approved SGLT2 inhibitors may be used to reduce the viability of pancreatic and prostate cancer cells in patients.